ZAPOTOCKA, Ester, Angelika BATOROVA, Ernest BILIC, Ana BOBAN, Carmen Escuriola ETTINGSHAUSEN, Barbara Faganel KOTNIK, Radomira HRDLICKOVA, Pawel LAGUNA, Jan MÁCHAL, Laszlo NEMES, Irena Preloznik ZUPAN, Gediminas PURAS and Marianna ZOMBORI. First experience of a hemophilia monitoring platform: florio HAEMO. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS. HOBOKEN: WILEY, 2022, vol. 6, No 2, p. 1-9. ISSN 2475-0379. Available from: https://dx.doi.org/10.1002/rth2.12685.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name First experience of a hemophilia monitoring platform: florio HAEMO
Authors ZAPOTOCKA, Ester (203 Czech Republic, guarantor), Angelika BATOROVA, Ernest BILIC, Ana BOBAN, Carmen Escuriola ETTINGSHAUSEN, Barbara Faganel KOTNIK, Radomira HRDLICKOVA, Pawel LAGUNA, Jan MÁCHAL (203 Czech Republic, belonging to the institution), Laszlo NEMES, Irena Preloznik ZUPAN, Gediminas PURAS and Marianna ZOMBORI.
Edition RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, HOBOKEN, WILEY, 2022, 2475-0379.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.600
RIV identification code RIV/00216224:14110/22:00128315
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/rth2.12685
UT WoS 000783276100005
Keywords in English hemophilia; patient preference; pharmacokinetics; telemedicine
Tags 14110317, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 22/2/2024 07:28.
Abstract
Background: florio HAEMO is a new hemophilia treatment monitoring application consisting of a patient smartphone application (app) and a web-based dashboard for healthcare professionals, providing several novel features, including activity tracking, wearable connectivity, kids and caregiver mode, and real-time pharmacokinetic factor level estimation. Objectives: To assess intuitiveness, ease-of-use, and patient preference of florio HAEMO in Central Europe using a cross-sectional survey. Methods: This survey was conducted in six Central European countries between 9 December 2020 and 24 May 2021, The online questionnaire included 17 questions about overall satisfaction, ease-of-use, intuitiveness, and patient preference. Adults or children with hemophilia on regular prophylaxis and using the florio HAEM app for a minimum of 1 week were invited to complete the online questionnaire by their treating physician. Results: Sixty-six participants took part in the survey. The median duration for all respondents using the florio HAEMO app was 3 to 4 weeks. Overall, 89.4% of users reported being very satisfied or rather satisfied after using florio HAEMO. Of the 23 respondents who had switched from another hemophilia app, 87.0% indicated that they strongly preferred or preferred using florio HAEMO. Most florio HAEMO users reported that the app was very easy or rather easy to use (97.0%) and intuitive (94.0%). florio HAEMO had a positive impact on daily living, with 78.8% of users reporting that the app was very important or rather important to them. Conclusions: This survey suggests that florio HAEMO is an easy-to-use and intuitive app to assist self-management of home prophylaxis.
PrintDisplayed: 28/7/2024 14:30